BMI as a predictive factor for benefit of extended endocrine therapy
overweight, overweight (B)
SECONDARY, OBESE
Overall, 1589 patients were included in the analysis on the predictive effect of BMI: 613 (38.6%) normal weight, 628 (39.5%) overweight, and 348 (21.9%) obese patients (In the total DATA study cohort (n = 1660), 6 versus 3 years of anastrozole resulted in a HR of 0.86 (95% CI = 0.72 to 1.01; The effect of 6 versus 3 years of anastrozole on aDFS was similar in normal weight (adjusted HR = 1.00; 95% CI = 0.74 to 1.35; Multivariable analyses of primary and secondary endpoints evaluating the efficacy of 6 vs 3 years of anastrozole, stratified by body mass index class at randomization.Adapted disease-free survival according to assigned treatment in normal weight (A), overweight (B), and obese (C) patients, and adapted overall survival according to assigned treatment in normal weight (D), overweight (E), and obese (F) patients. aDFS = adapted disease-free survival; aOS = adapted overall survival.In the analysis of aOS, the effect of 6 versus 3 years of anastrozole differed between normal weight (adjusted HR = 1.48; 95% CI = 0.98 to 2.23; Results of both adapted BCSM (aBCSM) and adapted OCM (aOCM) were comparable to those of aOS in every BMI class (Adapted breast cancer-specific mortality according to assigned treatment in normal weight (A), overweight (B), and obese (C) patients, and adapted other-cause mortality according to assigned treatment in normal weight (D), overweight (E), and obese (F) patients. aBCSM = adapted breast cancer-specific mortality; aOCM = adapted other-cause mortality.